ICHNO-ECHNO 2022 - Abstract Book

S72

ICHNO-ECHNO 2022

Materials and Methods A mixed method study design was used. OncologIQ was used during the multidisciplinary decision-making process for 38 patients. Quantitative outcome measures were: 1. perceived added value of the use of OncologIQ; 2. therapeutic doubt before and after the use of OncologIQ; and 3. adjustments in the multidisciplinary treatment plan due to OncologIQ. Qualitative data on user value was assessed through semi-structured interviews. Results In total, 419 measurements were retrieved from 18 healthcare professionals. In nearly half of the measurements (47.5%), healthcare professionals experienced added value upon using OncologIQ. OncologIQ was valued most in patients that were significantly older (p=0.02), had a WHO performance score of ≥ 2 (p=0.001), and tumor stage IV (p<0.001). A change in therapeutic doubt was seen in 100 measurements (23.8%). The multidisciplinary treatment plan changed once after the use of OncologIQ. Our qualitative findings suggest that OncologIQ is mostly valued in complex patients and is able to improve patient-centered care and holistic awareness (table).

Conclusion The use of the prognostic model OncologIQ is supportive to the decision-making process in a head and neck multidisciplinary team meeting. It enables patient-centered decision-making and is mostly valued in complex patients when confronted with therapeutic dilemmas.

PO-0119 OCT-4 – a simple test for cancer radiosensitivity.

H. Irjala 1 , J. Routila 2 , X. Qiao 3 , J. Weltner 4 , J. Rantala 5 , T. Carpen 6 , J. Hagstrom 6 , A. Makitie 6 , I. Leivo 7 , J. Soderlund 8 , M. Rintala 8 , S. Hietanen 8 , H. Minn 9 , J. Westermarck 10 , S. Ventela 11 1 Turku University Hospital, Otorhinolaryngology - Head and Neck Surgery, Turku, Finland; 2 Tuku University Hospital, Otorhinolaryngology - Head and Neck Surgery , Turku, Finland; 3 University of Turku, Turku Bioscience Centre, Turku, Finland; 4 Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Stockholm, Sweden; 5 Misvik Biology , Misvik Biology, turku, Finland; 6 Helsinki University Hospital, Otorhinolaryngology - Head and Neck Surgery , Helsinki, Finland; 7 Turku University, Pathology, Turku, Finland; 8 Turku University Hospital, Obstetrics and Gynecology, Turku, Finland; 9 Turku University Hospital, Oncology, Turku, Finland; 10 Turku University, Turku Bioscience Centre, Turku, Finland; 11 Turku University Hospital, Otorhinolaryngology - Head and Neck Surgery , Turku, Finland

Purpose or Objective Cisplatin is combined with radiotherapy for advanced head and neck

squamous cell carcinoma (HNSCC). While providing a beneficial effect on survival, it also causes side effects and thus is an important target when considering treatment de-escalation. Currently, there are no biomarkers to predict its patient-selective therapeutic utility. In this study, we examined the role of the stem cell factor OCT4 as a potential biomarker to help clinicians stratify HNSCC patients between radiotherapy and chemoradiotherapy. Materials and Methods OCT4 immunohistochemical staining of a population-validated tissue microarray (PV-TMA) (n= 166) representative of a standard HNSCC patients was carried out, and 5- year survival was analyzed. The results were validated using ex vivo drug sensitivity analysis of HNSCC tumor samples, and further cross-validated in independent oropharyngeal (n= 118), nasopharyngeal (n= 170), and vulvar carcinoma (n= 95) clinical datasets. In vitro, genetically modified, patient-derived HNSCC cells were used.